Table 1.
Basic demographics and disease characteristics of the RRMS, PPMS, and Soma cohorts.
| RRMS | PPMS | Soma | |
|---|---|---|---|
| Total no. patients | 71 | 16 | 30 |
| No. patients with serum samples | 63 | 16 | 28 |
| No. patients with CSF samples | 26 | 1 | 12 |
| No. patients with serum and CSF samples | 18 | 1 | 10 |
| Age (median [range]) | 36 [19–57] | 52 [43–70] | 29 [19–55] |
| Sex (% female) | 67.61 | 43.75 | 86.67 |
| Disease duration (median [range]) (Y) | 0.66 [0.00–19.73] | 4.76 [0.97–27.38] | n/a |
| CSF pleocytosis (% of patients) | 68.97 | 64.29 | 0 |
| BCSFBD (% of patients) | 39.22 | 55.56 | 14.81 |
| Positive OCBs (% of patients) | 88.06 | 92.86 | 0 |
| Positive MRZ (% of patients) | 44.44 | 55.56 | 0 |
| Intrathecal IgG synthesis (% of patients) | 85.97 | 92.86 | 0 |
| Intrathecal IgM synthesis (% of patients) | 21.74 | 20.00 | 0 |
| Intrathecal IgA synthesis (% of patients) | 17.39 | 0 | 0 |
BCSFBD—Blood–CSF-barrier dysfunction, CSF—Cerebrospinal fluid, Ig—Immunoglobulin, MRZ—Antibody indices (AI) against measles, rubella, and varicella zoster virus. MRZ was defined ‘positive’ if at least two out of three AI were higher than 1.5, No.—Number of, OCBs—Oligoclonal bands, PPMS—Primary progressive Multiple Sclerosis, RRMS—Relapsing–remitting Multiple Sclerosis, Soma—Somatic symptom disorder, Y—Years.